ERBB2 and breast cancer: Despite the advances in molecular classification of breast cancer [2–5], identifying of clinically relevant subgroups is still based on the status of estrogen and progesterone receptor (ER and PR) and human epidermal growth factor receptor 2 (HER2) along with clinicopathological variables.